PRJNA574649
Resolution of NASH and hepatic fibrosis by GLP-1R/GcgR dual-agonist MEDI0382 occurs via improved mitochondrial function and reduced lipogenesis
RNAseq analysis of gene expression in ob/ob mice subjected to chow, NASH-diet (AMLN), and a diet-reversal from AMLN to chow. The effect of MEDI0382-treatment in NASH mice was analyzed in comparison to chow-only and diet reversal.